US Dollar vs MXN

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

CGEN

Compugen (CGEN)

Compugen Ltd

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CGEN

1 2 3 4 5 6 7 8 9 10 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
20/05/2024	06:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:CGEN	Compugen Ltd
20/05/2024	06:00	PR Newswire (US)	Compugen Reports First Quarter 2024 Results	NASDAQ:CGEN	Compugen Ltd
20/05/2024	05:59	IH Market News	U.S. Index Futures Edge Slightly Higher in Pre-Market Trading, Oil Prices Dip	NASDAQ:CGEN	Compugen Ltd
16/05/2024	06:00	PR Newswire (US)	Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential	NASDAQ:CGEN	Compugen Ltd
15/05/2024	06:00	PR Newswire (US)	Compugen Appoints David Silberman as Chief Financial Officer	NASDAQ:CGEN	Compugen Ltd
06/05/2024	06:00	PR Newswire (US)	Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024	NASDAQ:CGEN	Compugen Ltd
25/04/2024	06:00	PR Newswire (US)	Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024	NASDAQ:CGEN	Compugen Ltd
10/04/2024	06:00	PR Newswire (US)	Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503	NASDAQ:CGEN	Compugen Ltd
03/04/2024	06:00	PR Newswire (US)	Compugen to Participate in Two Upcoming Investor Conferences	NASDAQ:CGEN	Compugen Ltd
11/03/2024	06:00	PR Newswire (US)	Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy	NASDAQ:CGEN	Compugen Ltd
06/03/2024	06:00	PR Newswire (US)	Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024	NASDAQ:CGEN	Compugen Ltd
05/03/2024	15:06	Edgar (US Regulatory)	Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]	NASDAQ:CGEN	Compugen Ltd
05/03/2024	06:00	PR Newswire (US)	Compugen Reports Fourth Quarter and Full Year 2023 Results	NASDAQ:CGEN	Compugen Ltd
05/03/2024	05:05	IH Market News	U.S. Futures Dip, Crude Oil Fluctuates	NASDAQ:CGEN	Compugen Ltd
26/02/2024	06:00	PR Newswire (US)	Compugen to Present at the Leerink Partners Global Biopharma Conference 2024	NASDAQ:CGEN	Compugen Ltd
20/02/2024	06:00	PR Newswire (US)	Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024	NASDAQ:CGEN	Compugen Ltd
15/02/2024	06:00	PR Newswire (US)	Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer	NASDAQ:CGEN	Compugen Ltd
08/01/2024	06:05	PR Newswire (US)	Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer	NASDAQ:CGEN	Compugen Ltd
08/01/2024	06:00	PR Newswire (US)	Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement	NASDAQ:CGEN	Compugen Ltd
19/12/2023	08:30	AllPennyStocks.com	Strong Open For Biotech Following Exclusive Agreement Announcement	NASDAQ:CGEN	Compugen Ltd
19/12/2023	06:10	PR Newswire (US)	Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer	NASDAQ:CGEN	Compugen Ltd
19/12/2023	06:05	PR Newswire (US)	Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology	NASDAQ:CGEN	Compugen Ltd
19/12/2023	06:00	Business Wire	Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program	NASDAQ:CGEN	Compugen Ltd
07/11/2023	06:00	PR Newswire (US)	Compugen Reports Third Quarter 2023 Results	NASDAQ:CGEN	Compugen Ltd
06/11/2023	06:00	PR Newswire (US)	Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy	NASDAQ:CGEN	Compugen Ltd
03/11/2023	15:35	PR Newswire (US)	Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification	NASDAQ:CGEN	Compugen Ltd
31/10/2023	08:00	PR Newswire (US)	Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer	NASDAQ:CGEN	Compugen Ltd
24/10/2023	06:00	PR Newswire (US)	Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023	NASDAQ:CGEN	Compugen Ltd
03/10/2023	06:00	PR Newswire (US)	Compugen to Present at Single Cell Genomics 2023 Meeting	NASDAQ:CGEN	Compugen Ltd
02/10/2023	06:00	PR Newswire (US)	Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer	NASDAQ:CGEN	Compugen Ltd

Showing the most relevant articles for your search:NASDAQ:CGEN

1 2 3 4 5 6 7 8 9 10 Próxima >

Imi Collezio Mc Ge26 Eur

RenoWorks Software

Dimensional Global ex US...

Vontobel Financial Produ...

Aristotle Growth Equity ...

Pgim Conservative Retire...

Cypress Hills Resource

Puretech Health (PK)

Idexx Laboratories

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones